FDA Brief

Warning letters Drugs

FDA warning letter to

Iotech International, LLC

High riskIssued Mar 15, 2022Posted Mar 17, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned Iotech International over ioRinse and ioCleanse marketed with unapproved COVID-19 prevention and treatment claims.

What happened

FDA and FTC reviewed Iotech International’s website and Facebook/Instagram pages in 2021 and 2022. The agencies found ioRinse and ioCleanse Molecular iodine Hand Cleanser sold with claims that they kill or inactivate coronavirus and help combat COVID-19. FDA said these are drugs and unapproved new drugs because no FDA-approved application is in effect.

What FDA found

  1. The products were sold as drugs intended to prevent or treat COVID-19 without FDA approval.

    section 505(a), FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded because they are nonprescription drugs that do not meet section 505G and lack an approved application.

    section 502(ee), FD&C Act, 21 U.S.C. § 352(ee)
  3. The COVID-19 claims go beyond the antiseptic uses allowed in the tentative drug monographs, so the products do not qualify for marketing without approval under section 505G(a)(3).

    section 505G(a)(3), FD&C Act, 21 U.S.C. § 355h(a)(3)
  4. ioCleanse labeling represents molecular iodine as an active ingredient that was not among the three Category III ingredients in the 1994 tentative final monograph for consumer antiseptic rubs.

    1994 TFM, 59 FR 31402; 21 CFR 201.66(b)(2)
  5. The website, social media, and linked article claims misleadingly represent the products as safe or effective for COVID-19.

    section 201(g)(1)(B)/(C), FD&C Act; 21 CFR 201.128
  6. FTC says the company lacked competent and reliable scientific evidence for claims that the products prevent, treat, or cure COVID-19.

    FTC Act, 15 U.S.C. § 41 et seq.; COVID-19 Consumer Protection Act

What FDA wants

FDA asks the company to stop selling unapproved COVID-19 products immediately and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and documentation. FTC separately asks for certification within 48 hours that the unsubstantiated claims have ceased.

Who should pay attention

  • companies selling antiseptic rinses or hand cleansers
  • brands making COVID-19 claims in labeling or social media
  • retailers and distributors of unapproved COVID-19 products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk